JP2008526866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526866A5 JP2008526866A5 JP2007550457A JP2007550457A JP2008526866A5 JP 2008526866 A5 JP2008526866 A5 JP 2008526866A5 JP 2007550457 A JP2007550457 A JP 2007550457A JP 2007550457 A JP2007550457 A JP 2007550457A JP 2008526866 A5 JP2008526866 A5 JP 2008526866A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- methyl
- biphenyl
- difluoro
- isonicotinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 57
- 125000000217 alkyl group Chemical group 0.000 claims 27
- 125000005843 halogen group Chemical group 0.000 claims 26
- 239000000651 prodrug Substances 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 239000012453 solvate Substances 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 125000001188 haloalkyl group Chemical group 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 125000004414 alkyl thio group Chemical group 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- -1 1H-tetrazolyl Chemical group 0.000 claims 7
- 125000000547 substituted alkyl group Chemical group 0.000 claims 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 6
- 125000003107 substituted aryl group Chemical group 0.000 claims 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 6
- 125000000335 thiazolyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims 5
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 3
- PUTFMOAOKZNUSN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(2h-tetrazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2NN=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F PUTFMOAOKZNUSN-UHFFFAOYSA-N 0.000 claims 3
- 102000004310 Ion Channels Human genes 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 230000005931 immune cell recruitment Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000001544 thienyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- NHEMHKBZHHLNLI-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2ON=CC=2)C)C=C1 NHEMHKBZHHLNLI-UHFFFAOYSA-N 0.000 claims 2
- XKTZWZSXRKNGGM-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C XKTZWZSXRKNGGM-UHFFFAOYSA-N 0.000 claims 2
- WIMBOLXNLFZPHG-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-oxazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=NC=2)C)C=C1 WIMBOLXNLFZPHG-UHFFFAOYSA-N 0.000 claims 2
- CMXASVOPXKZDOI-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)C)C=C1 CMXASVOPXKZDOI-UHFFFAOYSA-N 0.000 claims 2
- WQTHUZBGFPUICL-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(2h-tetrazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2NN=NN=2)C)C=C1 WQTHUZBGFPUICL-UHFFFAOYSA-N 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- ACZGJZKDSJLKPZ-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-5-pyridin-2-ylphenyl)phenyl]benzamide Chemical compound CC1=CC=C(C=2N=CC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F ACZGJZKDSJLKPZ-UHFFFAOYSA-N 0.000 claims 1
- RJOOCBTVZKGDSW-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-5-pyridin-3-ylphenyl)phenyl]benzamide Chemical compound CC1=CC=C(C=2C=NC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RJOOCBTVZKGDSW-UHFFFAOYSA-N 0.000 claims 1
- DYJBJACFGHRXMH-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-5-pyridin-4-ylphenyl)phenyl]benzamide Chemical compound CC1=CC=C(C=2C=CN=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DYJBJACFGHRXMH-UHFFFAOYSA-N 0.000 claims 1
- YCQQPBDGYUQILO-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methoxy-5-(1,3-oxazol-2-yl)phenyl]phenyl]benzamide Chemical compound COC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F YCQQPBDGYUQILO-UHFFFAOYSA-N 0.000 claims 1
- FRIGRPXYZRZZKE-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F FRIGRPXYZRZZKE-UHFFFAOYSA-N 0.000 claims 1
- PRCNEOSMANURNW-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F PRCNEOSMANURNW-UHFFFAOYSA-N 0.000 claims 1
- ZOHBMCUPFMAUSR-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F ZOHBMCUPFMAUSR-UHFFFAOYSA-N 0.000 claims 1
- VNYPBEICPYEHMU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-4-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2N=COC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VNYPBEICPYEHMU-UHFFFAOYSA-N 0.000 claims 1
- JJJUQDROKHOMAQ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2OC=NC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F JJJUQDROKHOMAQ-UHFFFAOYSA-N 0.000 claims 1
- HDILCULZLSYGHY-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1-methyltetrazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2N(N=NN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F HDILCULZLSYGHY-UHFFFAOYSA-N 0.000 claims 1
- VMGWUJGHNODFSG-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(1h-pyrrol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2NC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VMGWUJGHNODFSG-UHFFFAOYSA-N 0.000 claims 1
- FOBDRCIFVMXTIZ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(2-methyl-1,2,4-triazol-3-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2N(N=CN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F FOBDRCIFVMXTIZ-UHFFFAOYSA-N 0.000 claims 1
- LIODNSHJTIDZIW-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(2-methyltetrazol-5-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C2=NN(C)N=N2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F LIODNSHJTIDZIW-UHFFFAOYSA-N 0.000 claims 1
- HEYNONRWYRATQB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(3-methyl-1,2-oxazol-5-yl)phenyl]phenyl]benzamide Chemical compound O1N=C(C)C=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 HEYNONRWYRATQB-UHFFFAOYSA-N 0.000 claims 1
- GYWJWMIPARWTPX-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(4-methyl-1,3-thiazol-2-yl)phenyl]phenyl]benzamide Chemical compound CC1=CSC(C=2C=C(C(C)=CC=2)C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=N1 GYWJWMIPARWTPX-UHFFFAOYSA-N 0.000 claims 1
- DZXZUWXTRUTBAZ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)phenyl]phenyl]benzamide Chemical compound CN1C(SC)=NN=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 DZXZUWXTRUTBAZ-UHFFFAOYSA-N 0.000 claims 1
- XGHSASJTYJAMBM-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(5-methyl-1h-pyrazol-3-yl)phenyl]phenyl]benzamide Chemical compound N1N=C(C)C=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 XGHSASJTYJAMBM-UHFFFAOYSA-N 0.000 claims 1
- RBKOFVZSWPUDHN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-(5-oxo-2h-1,2,4-oxadiazol-3-yl)phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2NC(=O)ON=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RBKOFVZSWPUDHN-UHFFFAOYSA-N 0.000 claims 1
- ADNXESORVNANSH-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-methyl-5-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]phenyl]benzamide Chemical compound CC1=CC=C(C=2SC=C(N=2)C(F)(F)F)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F ADNXESORVNANSH-UHFFFAOYSA-N 0.000 claims 1
- HXUWFCJSAZOUHC-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methoxy-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound COC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F HXUWFCJSAZOUHC-UHFFFAOYSA-N 0.000 claims 1
- IBXFTAMPNIFRLP-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F IBXFTAMPNIFRLP-UHFFFAOYSA-N 0.000 claims 1
- GGFLWLCIACQRTN-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F GGFLWLCIACQRTN-UHFFFAOYSA-N 0.000 claims 1
- ABHZATVUDHEZLF-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F ABHZATVUDHEZLF-UHFFFAOYSA-N 0.000 claims 1
- YGSAGYAPEBUCNA-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=NC=C1F YGSAGYAPEBUCNA-UHFFFAOYSA-N 0.000 claims 1
- GUETUBNIKSOXBL-UHFFFAOYSA-N 3,5-difluoro-n-[4-[2-methyl-5-(4-methyl-5-methylsulfanyl-1,2,4-triazol-3-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CN1C(SC)=NN=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3F)F)=CC=2)=C1 GUETUBNIKSOXBL-UHFFFAOYSA-N 0.000 claims 1
- NMPQFYMAMREFNS-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3,4-oxadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F NMPQFYMAMREFNS-UHFFFAOYSA-N 0.000 claims 1
- FEUMTZNEZOBMOK-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F FEUMTZNEZOBMOK-UHFFFAOYSA-N 0.000 claims 1
- WPCGQXNFVBKJKW-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F WPCGQXNFVBKJKW-UHFFFAOYSA-N 0.000 claims 1
- QCEDPLCXHVYYHI-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3-oxazol-4-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2N=COC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F QCEDPLCXHVYYHI-UHFFFAOYSA-N 0.000 claims 1
- PJPOZVMUALBLIM-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F PJPOZVMUALBLIM-UHFFFAOYSA-N 0.000 claims 1
- MLZFLMBXBPPYEA-UHFFFAOYSA-N 3-fluoro-n-[4-[2-methyl-5-(2-methyl-1,2,4-triazol-3-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2N(N=CN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F MLZFLMBXBPPYEA-UHFFFAOYSA-N 0.000 claims 1
- CEIRNGJBZOTXOK-UHFFFAOYSA-N 3-methyl-n-[4-(2-methyl-5-pyridin-3-ylphenyl)phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2C=NC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C CEIRNGJBZOTXOK-UHFFFAOYSA-N 0.000 claims 1
- GONHYCZCLJNREV-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3,4-thiadiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2SC=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C GONHYCZCLJNREV-UHFFFAOYSA-N 0.000 claims 1
- ZNMMURJWVGDXBJ-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-oxazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)C)C=C1 ZNMMURJWVGDXBJ-UHFFFAOYSA-N 0.000 claims 1
- RWWRLUIPEDCHLY-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1,3-oxazol-4-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2N=COC=2)C)C=C1 RWWRLUIPEDCHLY-UHFFFAOYSA-N 0.000 claims 1
- AOUOIIJWWFSLCP-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(1-methyltetrazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CC=C(C=2N(N=NN=2)C)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C AOUOIIJWWFSLCP-UHFFFAOYSA-N 0.000 claims 1
- AXNLDNHUWVCRPF-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(3-methyl-1,2-oxazol-5-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound O1N=C(C)C=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=C1 AXNLDNHUWVCRPF-UHFFFAOYSA-N 0.000 claims 1
- FOHRUTIEUZNDIQ-UHFFFAOYSA-N 3-methyl-n-[4-[2-methyl-5-(4-methyl-1,3-thiazol-2-yl)phenyl]phenyl]pyridine-4-carboxamide Chemical compound CC1=CSC(C=2C=C(C(C)=CC=2)C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)=N1 FOHRUTIEUZNDIQ-UHFFFAOYSA-N 0.000 claims 1
- WOUMRZCHSWVQTK-UHFFFAOYSA-N 4-methyl-n-[4-(2-methyl-5-pyridin-2-ylphenyl)phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2N=CC=CC=2)C)=C1C WOUMRZCHSWVQTK-UHFFFAOYSA-N 0.000 claims 1
- CLGKUTCVDXQFFI-UHFFFAOYSA-N 4-methyl-n-[4-(2-methyl-5-pyridin-3-ylphenyl)phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2C=NC=CC=2)C)=C1C CLGKUTCVDXQFFI-UHFFFAOYSA-N 0.000 claims 1
- CLQLZLCGPUHVLW-UHFFFAOYSA-N 4-methyl-n-[4-[2-methyl-5-(1,2-oxazol-5-yl)phenyl]phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2ON=CC=2)C)=C1C CLQLZLCGPUHVLW-UHFFFAOYSA-N 0.000 claims 1
- PTTPWZUIZKXKGY-UHFFFAOYSA-N 4-methyl-n-[4-[2-methyl-5-(1,3-thiazol-2-yl)phenyl]phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)C=2C(=CC=C(C=2)C=2SC=CN=2)C)=C1C PTTPWZUIZKXKGY-UHFFFAOYSA-N 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- JKAOBMCPBFAEQR-UHFFFAOYSA-N methyl 3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 JKAOBMCPBFAEQR-UHFFFAOYSA-N 0.000 claims 1
- UUROVLXVZCQYKJ-UHFFFAOYSA-N methyl 3-[4-[(3,5-difluoropyridine-4-carbonyl)amino]phenyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3F)F)=CC=2)=C1 UUROVLXVZCQYKJ-UHFFFAOYSA-N 0.000 claims 1
- NOBHVWOAQXWKFL-UHFFFAOYSA-N methyl 3-[4-[(3-fluoropyridine-4-carbonyl)amino]phenyl]-4-methylbenzoate Chemical compound COC(=O)C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)=C1 NOBHVWOAQXWKFL-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- ZJYHCSIDRMVJCH-UHFFFAOYSA-N n-[4-(2-methoxy-5-thiophen-2-ylphenyl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C=2SC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C ZJYHCSIDRMVJCH-UHFFFAOYSA-N 0.000 claims 1
- REPOWMBMZCESPG-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxypyridin-3-yl)phenyl]-2,6-difluorobenzamide Chemical compound COC1=NC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F REPOWMBMZCESPG-UHFFFAOYSA-N 0.000 claims 1
- FFQDNYZYQQTJCY-UHFFFAOYSA-N n-[4-(5-chloro-2-methoxypyridin-3-yl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=NC=C(Cl)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C FFQDNYZYQQTJCY-UHFFFAOYSA-N 0.000 claims 1
- BVDBPRBGCAMVIK-UHFFFAOYSA-N n-[4-[2-(dimethylamino)-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CN(C)C1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C BVDBPRBGCAMVIK-UHFFFAOYSA-N 0.000 claims 1
- BIIGGBDTMAWGEQ-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=C1 BIIGGBDTMAWGEQ-UHFFFAOYSA-N 0.000 claims 1
- VJEMLWSCIVANKS-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3,5-difluoropyridine-4-carboxamide Chemical compound FC1=CN=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=C1 VJEMLWSCIVANKS-UHFFFAOYSA-N 0.000 claims 1
- DOIRCJTXASVGPW-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2OC=CN=2)Cl)C=C1 DOIRCJTXASVGPW-UHFFFAOYSA-N 0.000 claims 1
- FBPZZKCLQCACGD-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 FBPZZKCLQCACGD-UHFFFAOYSA-N 0.000 claims 1
- RRPPHAPIBOIGBN-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-3,5-difluoropyridine-4-carboxamide Chemical compound FC1=CN=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 RRPPHAPIBOIGBN-UHFFFAOYSA-N 0.000 claims 1
- CDXPRTPWAIUPGS-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 CDXPRTPWAIUPGS-UHFFFAOYSA-N 0.000 claims 1
- JOMGPQQJXLLZEM-UHFFFAOYSA-N n-[4-[2-chloro-5-(1,3-thiazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound CC1=CN=CC=C1C(=O)NC1=CC=C(C=2C(=CC=C(C=2)C=2SC=CN=2)Cl)C=C1 JOMGPQQJXLLZEM-UHFFFAOYSA-N 0.000 claims 1
- KOKVANSMRRJMMS-UHFFFAOYSA-N n-[4-[2-methoxy-5-(1,3-oxazol-2-yl)phenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C=2OC=CN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C KOKVANSMRRJMMS-UHFFFAOYSA-N 0.000 claims 1
- SOOVPSRHNUYTBZ-UHFFFAOYSA-N n-[4-[2-methoxy-5-(1,3-oxazol-5-yl)phenyl]phenyl]-4-methylthiadiazole-5-carboxamide Chemical compound COC1=CC=C(C=2OC=NC=2)C=C1C(C=C1)=CC=C1NC(=O)C=1SN=NC=1C SOOVPSRHNUYTBZ-UHFFFAOYSA-N 0.000 claims 1
- OSZIQZHRROTGTD-UHFFFAOYSA-N n-[4-[5-(5-amino-1,3,4-thiadiazol-2-yl)-2-methylphenyl]phenyl]-2,6-difluorobenzamide Chemical compound CC1=CC=C(C=2SC(N)=NN=2)C=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F OSZIQZHRROTGTD-UHFFFAOYSA-N 0.000 claims 1
- GEXVQFXUKFJYCI-UHFFFAOYSA-N n-[4-[5-(furan-2-yl)-2-methoxyphenyl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound COC1=CC=C(C=2OC=CC=2)C=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C GEXVQFXUKFJYCI-UHFFFAOYSA-N 0.000 claims 1
- PKVFLLHAPLTWRZ-UHFFFAOYSA-N n-[4-[5-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-2-methylphenyl]phenyl]-2,6-difluoro-n-methylbenzamide Chemical compound S1C(N(C)C)=NN=C1C1=CC=C(C)C(C=2C=CC(=CC=2)N(C)C(=O)C=2C(=CC=CC=2F)F)=C1 PKVFLLHAPLTWRZ-UHFFFAOYSA-N 0.000 claims 1
- BZUOMZUMVYMSMW-UHFFFAOYSA-N n-[4-[5-[5-(dimethylamino)-1,3,4-thiadiazol-2-yl]-2-methylphenyl]phenyl]-2,6-difluorobenzamide Chemical compound S1C(N(C)C)=NN=C1C1=CC=C(C)C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 BZUOMZUMVYMSMW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 0 *C1C=CC(*)=CC1c(cc1)ccc1I* Chemical compound *C1C=CC(*)=CC1c(cc1)ccc1I* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64217905P | 2005-01-07 | 2005-01-07 | |
| US60/642,179 | 2005-01-07 | ||
| US70784505P | 2005-08-12 | 2005-08-12 | |
| US60/707,845 | 2005-08-12 | ||
| PCT/US2006/000296 WO2006083477A2 (en) | 2005-01-07 | 2006-01-06 | Compounds for inflammation and immune-related uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012100291A Division JP2012176959A (ja) | 2005-01-07 | 2012-04-25 | 炎症及び免疫に関連する用途に用いる化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008526866A JP2008526866A (ja) | 2008-07-24 |
| JP2008526866A5 true JP2008526866A5 (https=) | 2009-02-19 |
| JP5184891B2 JP5184891B2 (ja) | 2013-04-17 |
Family
ID=36777716
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007550457A Expired - Fee Related JP5184891B2 (ja) | 2005-01-07 | 2006-01-06 | 炎症及び免疫に関連する用途に用いる化合物 |
| JP2012100291A Pending JP2012176959A (ja) | 2005-01-07 | 2012-04-25 | 炎症及び免疫に関連する用途に用いる化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012100291A Pending JP2012176959A (ja) | 2005-01-07 | 2012-04-25 | 炎症及び免疫に関連する用途に用いる化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US8202999B2 (https=) |
| EP (1) | EP1846372B1 (https=) |
| JP (2) | JP5184891B2 (https=) |
| KR (2) | KR20070107022A (https=) |
| AU (1) | AU2006211646B2 (https=) |
| BR (1) | BRPI0606476A2 (https=) |
| CA (1) | CA2593550A1 (https=) |
| IL (1) | IL184445A0 (https=) |
| MX (1) | MX2007008290A (https=) |
| NZ (1) | NZ556546A (https=) |
| TW (1) | TWI441819B (https=) |
| WO (1) | WO2006083477A2 (https=) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1848435T3 (pl) | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| TWI444187B (zh) * | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
| WO2007031791A1 (en) * | 2005-09-16 | 2007-03-22 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| RU2416603C9 (ru) | 2005-10-25 | 2012-06-20 | Сионоги Энд Ко., Лтд. | Производные аминодигидротиазина |
| WO2007087442A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| WO2007087441A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| US20070254926A1 (en) * | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| US8119643B2 (en) * | 2006-03-20 | 2012-02-21 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| EP2054383A2 (en) * | 2006-08-09 | 2009-05-06 | SmithKline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| CA2669695C (en) * | 2006-11-13 | 2012-10-30 | Synta Pharmaceuticals Corp. | Tetrahydropyridinyl compounds for inflammation and immune-related uses |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP2147914B1 (en) * | 2007-04-24 | 2014-06-04 | Shionogi&Co., Ltd. | Aminodihydrothiazine derivatives substituted with cyclic groups |
| TW200911800A (en) * | 2007-08-01 | 2009-03-16 | Synta Pharmaceuticals Corp | Pyridine compounds for inflammation and immune-related uses |
| US8349841B2 (en) * | 2007-08-01 | 2013-01-08 | Synta Pharmaceuticals Corp. | Vinyl-aryl derivatives for inflammation and immune-related uses |
| JP5411141B2 (ja) | 2007-09-10 | 2014-02-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| CA2722582A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf. | Biaryl pde4 inhibitors for treating inflammation |
| KR20100098653A (ko) | 2007-11-21 | 2010-09-08 | 디코드 제네틱스 이에이치에프 | 염증의 치료를 위한 바이아릴 ｐｄｅ４ 억제제 |
| US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8063152B2 (en) * | 2008-03-17 | 2011-11-22 | The Goodyear Tire & Rubber Company | Boron containing functionalizing agent |
| WO2009151098A1 (ja) * | 2008-06-13 | 2009-12-17 | 塩野義製薬株式会社 | βセクレターゼ阻害作用を有する含硫黄複素環誘導体 |
| US7906553B2 (en) | 2008-08-27 | 2011-03-15 | Calcimedica, Inc. | Substituted thiophene modulators of intracellular calcium |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| EP2350006A1 (en) * | 2008-10-01 | 2011-08-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| EP2350064A1 (en) * | 2008-10-01 | 2011-08-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8143269B2 (en) | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| CN102186841A (zh) * | 2008-10-22 | 2011-09-14 | 盐野义制药株式会社 | 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物 |
| WO2011034962A2 (en) | 2009-09-16 | 2011-03-24 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US8377970B2 (en) * | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| TWI488852B (zh) | 2009-12-11 | 2015-06-21 | Shionogi & Co | 衍生物 |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2011248579A1 (en) * | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| DK2563776T3 (en) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Relations that modulate intracellular calcium |
| EP2609095A4 (en) | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| JP5816630B2 (ja) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | ナフチリジン誘導体 |
| JP5766198B2 (ja) | 2010-10-29 | 2015-08-19 | 塩野義製薬株式会社 | 縮合アミノジヒドロピリミジン誘導体 |
| BR112013010643A2 (pt) | 2010-10-30 | 2016-08-09 | Lupin Ltd | compostos heterocíclicos |
| TW201247635A (en) | 2011-04-26 | 2012-12-01 | Shionogi & Co | Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them |
| EP2704701B1 (en) * | 2011-05-03 | 2018-01-03 | PRCL Research Inc. | Compounds for inflammation and immune-related uses |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| KR101373705B1 (ko) * | 2011-08-05 | 2014-03-14 | 동국대학교 산학협력단 | 신규한 바이페닐 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 염증성 질환 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| BR112014005935A2 (pt) | 2011-09-16 | 2017-03-28 | Fovea Pharmaceuticals | derivados de anilina, sua preparação e sua aplicação terapêutica |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013063458A2 (en) * | 2011-10-27 | 2013-05-02 | Mayo Foundation For Medical Education And Research | Inhibiting g protein coupled receptor 6 kinase polypeptides |
| WO2013164769A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| WO2013164773A1 (en) | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyrazole compounds as crac modulators |
| WO2014008214A1 (en) * | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2912035A4 (en) | 2012-10-24 | 2016-06-15 | Shionogi & Co | DERIVATIVES OF DIHYDROOXAZINE OR OXAZEPINE HAVING BACE1 INHIBITING ACTIVITY |
| TR201302590A2 (tr) * | 2013-03-04 | 2014-09-22 | S Gueniz Kuecuekguezel | Diflunisalden hareketle yeni bileşiklerin sentezi. |
| EP3010586A1 (en) | 2013-06-21 | 2016-04-27 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| US9790231B2 (en) | 2013-06-24 | 2017-10-17 | Lupin Limited | Chromane and chromene derivatives and their use as CRAC modulators |
| AU2014342338B2 (en) * | 2013-11-01 | 2016-12-01 | Novartis Ag | Aminoheteroaryl benzamides as kinase inhibitors |
| WO2015090579A1 (en) * | 2013-12-18 | 2015-06-25 | Grünenthal GmbH | Pyrazolyl-based carboxamides iv |
| EP3134399A4 (en) | 2014-04-21 | 2017-12-27 | Mayo Foundation for Medical Education and Research | Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides |
| ES3033759T3 (en) | 2015-02-27 | 2025-08-07 | Calcimedica Inc | Pancreatitis treatment |
| KR101796391B1 (ko) | 2015-07-24 | 2017-11-09 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
| WO2017018751A1 (ko) * | 2015-07-24 | 2017-02-02 | 동국대학교 산학협력단 | Blt 저해 활성을 갖는 신규 화합물 및 이를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 조성물 |
| CN108026026B (zh) | 2015-08-03 | 2021-02-09 | 夸德里加生物科学公司 | 作为化疗剂的β-取代的β-氨基酸和类似物及其应用 |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| TWI780046B (zh) * | 2016-05-10 | 2022-10-11 | 國立大學法人東京醫科齒科大學 | 炎症促進因子表現抑制劑、其有效成分之篩選方法、對於該方法為有用之表現匣、診斷藥及診斷方法 |
| SG11202004097RA (en) | 2017-11-09 | 2020-06-29 | Univ Nat Corp Tokyo Medical & Dental | Inhibitor of the expression of cancer-promoting factors, screening method for active ingredient thereof, expression cassette useful in said method, diagnostic drug, and diagnostic method |
| US10766900B2 (en) * | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| SG11202102491RA (en) | 2018-09-14 | 2021-04-29 | Rhizen Pharmaceuticals A G | Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof |
| KR20220140515A (ko) | 2020-01-13 | 2022-10-18 | 버지 애널리틱스, 인크. | 치환된 피라졸로-피리미딘 및 그의 용도 |
| CA3172249A1 (en) | 2020-03-20 | 2021-09-23 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| CA3198798A1 (en) | 2020-11-13 | 2022-05-19 | Kenneth Stauderman | Improved synthesis of crac channel inhibitors |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| GB2273930A (en) | 1992-12-30 | 1994-07-06 | Glaxo Group Ltd | Benzanilide derivatives |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| GB2276163A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Pyridine compounds. |
| GB2276161A (en) | 1993-03-17 | 1994-09-21 | Glaxo Group Ltd | Aniline and benzanilide derivatives |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE69632548T2 (de) | 1995-12-21 | 2005-06-02 | Bristol-Myers Squibb Pharma Co. | ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US6187797B1 (en) | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| CN1246847A (zh) | 1996-12-23 | 2000-03-08 | 杜邦药品公司 | 作为Xa因子抑制剂的含氮杂芳族化合物 |
| CA2276034A1 (en) | 1996-12-23 | 1998-07-02 | Mimi Lifen Quan | Oxygen or sulfur containing 5-membered heteroaromatics as factor xa inhibitors |
| KR20010013977A (ko) | 1997-06-19 | 2001-02-26 | 블레어 큐. 퍼거슨 | 중성 ｐ1 특이성 기를 갖는 인자 ｘａ의 억제제 |
| US6060491A (en) | 1997-06-19 | 2000-05-09 | Dupont Pharmaceuticals | 6-membered aromatics as factor Xa inhibitors |
| WO1998057934A1 (en) | 1997-06-19 | 1998-12-23 | The Du Pont Merck Pharmaceutical Company | (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS |
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| IL136637A0 (en) | 1997-12-22 | 2001-06-14 | Du Pont Pharm Co | Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors |
| DE69921358T2 (de) | 1998-12-23 | 2006-03-09 | Bristol-Myers Squibb Pharma Co. | Stickstoffhaltige heterobicyclen als faktor-xa-hemmer |
| CA2361428A1 (en) | 1999-02-11 | 2000-08-17 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| JP2002538226A (ja) | 1999-03-11 | 2002-11-12 | デュポン ファーマシューティカルズ カンパニー | Ｘａ因子阻害剤およびアスピリン、組織プラスミノーゲンアクチベータ（ＴＰＡ）、ＧＰＩＩｂ／ＩＩＩａ拮抗剤、低分子量ヘパリンまたはヘパリンの組合せ使用による血栓症の治療 |
| US6632815B2 (en) | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| US6844367B1 (en) | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
| JP2003509412A (ja) | 1999-09-17 | 2003-03-11 | シーオーアール セラピューティクス インコーポレイテッド | Ｘａ因子阻害剤 |
| US6720317B1 (en) | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| DE60040676D1 (de) | 1999-09-17 | 2008-12-11 | Millennium Pharm Inc | BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa |
| US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
| WO2001032628A1 (en) | 1999-11-03 | 2001-05-10 | Bristol-Myers Squibb Pharma Company | Cyano compounds as factor xa inhibitors |
| JP2003523356A (ja) | 2000-01-29 | 2003-08-05 | エルジー シーアイ リミテッド | アリール−アミジンを持つＸａ因子阻害剤とその誘導体、及びそれらのプロドラッグ |
| DE10008329A1 (de) | 2000-02-23 | 2001-08-30 | Merck Patent Gmbh | Aminosulfonylbiphenylderivate |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| EP1285651B1 (en) | 2000-04-28 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonists |
| AU2001268711A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| DE10035144A1 (de) | 2000-07-19 | 2002-01-31 | Merck Patent Gmbh | Cyclische Aminosäurederivate |
| US7283874B2 (en) | 2000-10-16 | 2007-10-16 | Remon Medical Technologies Ltd. | Acoustically powered implantable stimulating device |
| GB0106586D0 (en) | 2001-03-16 | 2001-05-09 | Smithkline Beecham Plc | Novel compounds |
| US7074801B1 (en) | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| WO2003005025A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| GB0124928D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| GB0124932D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| WO2004011427A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
| US20040029920A1 (en) | 2002-08-06 | 2004-02-12 | Kuduk Scott D. | 2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives |
| WO2004056774A2 (en) | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| CN1826121B (zh) * | 2003-07-23 | 2013-05-29 | 幸讬制药公司 | 苯基与吡啶基衍生物用于制备调控钙离子释放活化钙离子通道的药物的用途 |
| GB0325031D0 (en) | 2003-10-27 | 2003-12-03 | Novartis Ag | Organic compounds |
| JP5299810B2 (ja) * | 2004-02-27 | 2013-09-25 | アムジエン・インコーポレーテツド | 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法 |
| TW200619191A (en) * | 2004-10-27 | 2006-06-16 | Sankyo Co | Phenyl compounds with more than 2 substitutes |
-
2006
- 2006-01-06 KR KR1020077017923A patent/KR20070107022A/ko not_active Ceased
- 2006-01-06 US US11/326,872 patent/US8202999B2/en not_active Expired - Fee Related
- 2006-01-06 AU AU2006211646A patent/AU2006211646B2/en not_active Ceased
- 2006-01-06 CA CA002593550A patent/CA2593550A1/en not_active Abandoned
- 2006-01-06 BR BRPI0606476-0A patent/BRPI0606476A2/pt not_active IP Right Cessation
- 2006-01-06 NZ NZ556546A patent/NZ556546A/en not_active IP Right Cessation
- 2006-01-06 TW TW095100558A patent/TWI441819B/zh not_active IP Right Cessation
- 2006-01-06 KR KR1020137034625A patent/KR20140018997A/ko not_active Ceased
- 2006-01-06 EP EP06733619.8A patent/EP1846372B1/en not_active Expired - Lifetime
- 2006-01-06 MX MX2007008290A patent/MX2007008290A/es active IP Right Grant
- 2006-01-06 JP JP2007550457A patent/JP5184891B2/ja not_active Expired - Fee Related
- 2006-01-06 WO PCT/US2006/000296 patent/WO2006083477A2/en not_active Ceased
-
2007
- 2007-07-05 IL IL184445A patent/IL184445A0/en unknown
-
2012
- 2012-04-25 JP JP2012100291A patent/JP2012176959A/ja active Pending
- 2012-05-14 US US13/470,772 patent/US8592486B2/en not_active Expired - Fee Related
-
2013
- 2013-10-15 US US14/053,896 patent/US20140039009A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526866A5 (https=) | ||
| JP2009525285A5 (https=) | ||
| JP2009524678A5 (https=) | ||
| JP2009524677A5 (https=) | ||
| AU2007208225B2 (en) | Thiazole and thiadiazole compounds for inflammation and immune-related uses | |
| JP2009524683A5 (https=) | ||
| AU2006211646B2 (en) | Compounds for inflammation and immune-related uses | |
| AU2007211276B2 (en) | Pyridylphenyl compounds for inflammation and immune-related uses | |
| JP2009529059A5 (https=) | ||
| JP2007523905A5 (https=) | ||
| JP2019517455A5 (https=) | ||
| JP2007519735A5 (https=) | ||
| JP2008528520A5 (https=) | ||
| RU2013139662A (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| CA2484159A1 (en) | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | |
| JP2013505901A5 (https=) | ||
| RU2012111125A (ru) | N-(1, 2, 5- оксадиазол-3-ил)бензамиды и их применение в качестве гербицидов | |
| RU2005129729A (ru) | Производные гетероарилкарбамоилбензола | |
| JP2006506340A5 (https=) | ||
| JP2007523142A5 (https=) | ||
| JP2010540462A5 (https=) | ||
| CA2684105A1 (en) | Pyridine derivatives | |
| JP2010506825A5 (https=) | ||
| WO2012047966A4 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| JP2018507234A5 (https=) |